Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals metabolic changes in gynecologic cancer patients after treatment

NCT ID NCT07393633

Knowledge-focused Sponsor: University of Tennessee Graduate School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a single round of chemotherapy or immunotherapy changes the way the body uses energy and fats in women with gynecologic cancers. Researchers measured breathing and blood markers in 43 participants before and after treatment. The goal was to learn more about how cancer therapies affect whole-body metabolism, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Aug 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with gynecologic cancer engaged in active treatment.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women * Age \>18 years * Biopsy confirmed gynecologic cancer. * Scheduled to or currently undergoing infusion therapy. * Receiving cytotoxic chemotherapy or immunotherapy. Exclusion Criteria: * Inability to provide voluntary informed consent. * Received inpatient medical intervention for adverse effects of chemotherapy. * Circumstances and/or medical condition that would limit compliance with study requirements and protocol, as determined by the principal investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gynecologic cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

female reproductive organ cancer ovarian cancer uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gynecologic cancers

Contacts and locations

Locations

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.